Search:
Professors
Shibo Jiang
发表时间:2019-04-19 阅读次数:1881次

Dr. Shibo Jiang, Professor and Director, Institute of Medical Microbiology. He obtained his MS and MD degrees from the First and  Fourth Medical University of PLA, respectively. In 1987-1990, he received his postdoctoral training in the Laboratory of Cellular Physiology and Immunology, the Rockefeller University in New York. From 1990 to 2010, he had worked in the Lindsley F. Kimball Research Institute of the New York Blood Center as Assistant Member, Associate Member, Member, and Head of Viral Immunology Laboratory. Since 2010, he has worked as a professor in the Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), Shanghai Medical School, Fudan University, Shanghai, China.
 
His major research interest is to develop antiviral therapeutics and vaccines against HIV, RSV, HPV, SARS-CoV, MERS-CoV, EBOV, ZIKV, NiV, LASV and influenza viruses. In the early of 1990s, his group discovered the first highly potent anti-HIV C-peptide, SJ-2176 (Nature 365:113, 1993), and his patent (USP 5,444,044) was licensed to Trimeris Pharmaceuticals for the development of the first viral entry inhibitor-based anti-HIV drug, T-20 (enfuvirtide, Fuzeon). Using the similar approaches, his group identified the fusion inhibitory peptides against SARS-CoV, MERS-CoV, and other human coronaviruses. His team has also developed the most effective and safe subunit vaccine candidates against SARS-CoV and MERS-CoV. He has pioneered the study on the development of microbicides for preventing HIV sexual transmission. In the early of 2010s, his group found that an anhydride modified protein (JB-01) can effectively inhibit the infection of sexually transmitted viruses, HPV and HIV, and their patents were licensed to Shanxi Jinbo Biopharmaceutical Co., Ltd. to develop an "anti-HPV biological protein dressing", which was approval by Shanxi Provincial Food and Drug Administration in 2012 and has been used in hundreds of hospitals in China. It has shown excellent safety and efficacy. A lubricant product containing JB-01 was also approved as a complementary measure to prevent the sexual transmission of HIV and HPV.
 
So far, he has published 428 peer-reviewed papers in English SCI journals (https://www.ncbi.nlm.nih.gov/myncbi/browse/collection/48247255/?sort=date&direction=descending), including Nature, Nature Medicine (x2), Lancet (x3), Nature Communication (x6), PNAS (x4), Journal of Experimental Medicine (x2), Nature Review Microbiology, Cell, Science Advance, Science Translation Medicine etc. with >15,000 citations. His h-index is 63 (Google Scholar). He has applied for 32 US patents (24 of them were issued), and 48 Chinese and PCT patents (14 of them were issued), and 11 patents have been licensed out. As a PI, he has received 9 grants (>20 million USD) from NIH of the United States and 9 grants (>20 million RMB) from Chinese foundations. He has given >220 oral presentations at international conferences, academic institutions and pharmaceutical companies in >40 countries and regions.
 
Dr. Jiang has served as an Editorial Consultant for The Lancet, Scientific Editor for PLoS ONE, Editorial Board Member for Emerging Microbes and Infection, Antiviral Research, Retrovirology, Biochim Biophys Acta, and Microbes and Infection, and ad hoc referee for more than 80 international journals. He has acted as a grant reviewer for the NIH of the United States, the Research Grants Council (RGC) of Hong Kong, the Natural Science Foundation of China (NSFC), the Canadian Institutes of Health Research (CIHR), and the Agency for Science, Technology and Research (A*STAR) of Singapore.
 

 

Copyright 2012 ◎ Basic Medical College of Fudan University
Address: Shanghai Medical College Road 138 Tel :21 -54237900 Fax: 021-64179832